Roth Capital Initiates Coverage On Apellis Pharmaceuticals with Buy Rating, Announces Price Target of $31 - Apellis Pharmaceuticals (NASDAQ:APLS)
Published on March 13, 2026.
Roth Capital has initiated a review of Apellis Pharmaceuticals with a Buy-out rating and a price target of $31. The company's focus is on improving the quality of the pharmaceutical industry. The article also mentions that the company is looking into the future of the industry.
Related Articles
Jefferies Maintains Buy on MasTec, Raises Price Target to $348 - MasTec (NYSE:MTZ)
Jeff.com reveals details of the $10,000 price tag for an upcoming episode of The Great British Bake Off:.
Billionaire who broke Bank of England issues dire warning on dollar
Stanley Druckenmiller, a billionaire investor known for breaking Bank of England rules, affirms the U.S. dollar’s status as a global reserve currency and expresses skepticism for crypto.
Wall Street Icon Warns: Waiting for Perfect Info Will Keep You on the Sidelines — How Top Traders Get In Early
Stan Druckenmiller warns that overanalysis can hinder active traders, emphasizing the importance of knowing their potential risks and building a cohesive strategy.